The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
A correction has been published: N Engl J Med 2005;353(17):1869.

Correspondence
PreviousPrevious
Volume 353:627-630 August 11, 2005 Number 6
NextNext

Amiodarone versus Sotalol for Atrial Fibrillation

Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

 Sign up for free e-toc
 

This Article
-Full Text
- PDF
-PDA Full Text
-Purchase this article

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited
-E-mail When Letters Appear

More Information
-Related Article
-Related Article
by Singh, B. N.
-PubMed Citation
To the Editor: Singh et al. (May 5 issue)1 report in their article that both amiodarone and sotalol are efficacious in improving quality of life and sustaining sinus rhythm in patients with atrial fibrillation. They also report, but dismiss as statistically insignificant, a higher incidence of death in both groups of patients as compared with the placebo group.

On the basis of their data, the absolute increase in the risk of death in the amiodarone and the sotalol groups, as compared with the placebo group, was 2.7 and 3.6 percentage points, respectively, with a number needed to harm of between . . . [Full Text of this Article]



HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.